Cargando…

Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition

BACKGROUND: The RTOG 94-13 trial has provided evidence that patients with high risk prostate cancer benefit from an additional radiotherapy to the pelvic nodes combined with concomitant hormonal ablation. Since lymphatic drainage of the prostate is highly variable, the optimal target volume definiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganswindt, Ute, Paulsen, Frank, Corvin, Stefan, Eichhorn, Kai, Glocker, Stefan, Hundt, Ilse, Birkner, Mattias, Alber, Markus, Anastasiadis, Aristotelis, Stenzl, Arnulf, Bares, Roland, Budach, Wilfried, Bamberg, Michael, Belka, Claus
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1190164/
https://www.ncbi.nlm.nih.gov/pubmed/16048656
http://dx.doi.org/10.1186/1471-2407-5-91
_version_ 1782124795907801088
author Ganswindt, Ute
Paulsen, Frank
Corvin, Stefan
Eichhorn, Kai
Glocker, Stefan
Hundt, Ilse
Birkner, Mattias
Alber, Markus
Anastasiadis, Aristotelis
Stenzl, Arnulf
Bares, Roland
Budach, Wilfried
Bamberg, Michael
Belka, Claus
author_facet Ganswindt, Ute
Paulsen, Frank
Corvin, Stefan
Eichhorn, Kai
Glocker, Stefan
Hundt, Ilse
Birkner, Mattias
Alber, Markus
Anastasiadis, Aristotelis
Stenzl, Arnulf
Bares, Roland
Budach, Wilfried
Bamberg, Michael
Belka, Claus
author_sort Ganswindt, Ute
collection PubMed
description BACKGROUND: The RTOG 94-13 trial has provided evidence that patients with high risk prostate cancer benefit from an additional radiotherapy to the pelvic nodes combined with concomitant hormonal ablation. Since lymphatic drainage of the prostate is highly variable, the optimal target volume definition for the pelvic lymph nodes is problematic. To overcome this limitation, we tested the feasibility of an intensity modulated radiation therapy (IMRT) protocol, taking under consideration the individual pelvic sentinel node drainage pattern by SPECT functional imaging. METHODS: Patients with high risk prostate cancer were included. Sentinel nodes (SN) were localised 1.5–3 hours after injection of 250 MBq (99m)Tc-Nanocoll using a double-headed gamma camera with an integrated X-Ray device. All sentinel node localisations were included into the pelvic clinical target volume (CTV). Dose prescriptions were 50.4 Gy (5 × 1.8 Gy / week) to the pelvis and 70.0 Gy (5 × 2.0 Gy / week) to the prostate including the base of seminal vesicles or whole seminal vesicles. Patients were treated with IMRT. Furthermore a theoretical comparison between IMRT and a three-dimensional conformal technique was performed. RESULTS: Since 08/2003 6 patients were treated with this protocol. All patients had detectable sentinel lymph nodes (total 29). 4 of 6 patients showed sentinel node localisations (total 10), that would not have been treated adequately with CT-based planning ('geographical miss') only. The most common localisation for a probable geographical miss was the perirectal area. The comparison between dose-volume-histograms of IMRT- and conventional CT-planning demonstrated clear superiority of IMRT when all sentinel lymph nodes were included. IMRT allowed a significantly better sparing of normal tissue and reduced volumes of small bowel, large bowel and rectum irradiated with critical doses. No gastrointestinal or genitourinary acute toxicity Grade 3 or 4 (RTOG) occurred. CONCLUSION: IMRT based on sentinel lymph node identification is feasible and reduces the probability of a geographical miss. Furthermore, IMRT allows a pronounced sparing of normal tissue irradiation. Thus, the chosen approach will help to increase the curative potential of radiotherapy in high risk prostate cancer patients.
format Text
id pubmed-1190164
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-11901642005-08-25 Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition Ganswindt, Ute Paulsen, Frank Corvin, Stefan Eichhorn, Kai Glocker, Stefan Hundt, Ilse Birkner, Mattias Alber, Markus Anastasiadis, Aristotelis Stenzl, Arnulf Bares, Roland Budach, Wilfried Bamberg, Michael Belka, Claus BMC Cancer Research Article BACKGROUND: The RTOG 94-13 trial has provided evidence that patients with high risk prostate cancer benefit from an additional radiotherapy to the pelvic nodes combined with concomitant hormonal ablation. Since lymphatic drainage of the prostate is highly variable, the optimal target volume definition for the pelvic lymph nodes is problematic. To overcome this limitation, we tested the feasibility of an intensity modulated radiation therapy (IMRT) protocol, taking under consideration the individual pelvic sentinel node drainage pattern by SPECT functional imaging. METHODS: Patients with high risk prostate cancer were included. Sentinel nodes (SN) were localised 1.5–3 hours after injection of 250 MBq (99m)Tc-Nanocoll using a double-headed gamma camera with an integrated X-Ray device. All sentinel node localisations were included into the pelvic clinical target volume (CTV). Dose prescriptions were 50.4 Gy (5 × 1.8 Gy / week) to the pelvis and 70.0 Gy (5 × 2.0 Gy / week) to the prostate including the base of seminal vesicles or whole seminal vesicles. Patients were treated with IMRT. Furthermore a theoretical comparison between IMRT and a three-dimensional conformal technique was performed. RESULTS: Since 08/2003 6 patients were treated with this protocol. All patients had detectable sentinel lymph nodes (total 29). 4 of 6 patients showed sentinel node localisations (total 10), that would not have been treated adequately with CT-based planning ('geographical miss') only. The most common localisation for a probable geographical miss was the perirectal area. The comparison between dose-volume-histograms of IMRT- and conventional CT-planning demonstrated clear superiority of IMRT when all sentinel lymph nodes were included. IMRT allowed a significantly better sparing of normal tissue and reduced volumes of small bowel, large bowel and rectum irradiated with critical doses. No gastrointestinal or genitourinary acute toxicity Grade 3 or 4 (RTOG) occurred. CONCLUSION: IMRT based on sentinel lymph node identification is feasible and reduces the probability of a geographical miss. Furthermore, IMRT allows a pronounced sparing of normal tissue irradiation. Thus, the chosen approach will help to increase the curative potential of radiotherapy in high risk prostate cancer patients. BioMed Central 2005-07-28 /pmc/articles/PMC1190164/ /pubmed/16048656 http://dx.doi.org/10.1186/1471-2407-5-91 Text en Copyright © 2005 Ganswindt et al; licensee BioMed Central Ltd.
spellingShingle Research Article
Ganswindt, Ute
Paulsen, Frank
Corvin, Stefan
Eichhorn, Kai
Glocker, Stefan
Hundt, Ilse
Birkner, Mattias
Alber, Markus
Anastasiadis, Aristotelis
Stenzl, Arnulf
Bares, Roland
Budach, Wilfried
Bamberg, Michael
Belka, Claus
Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition
title Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition
title_full Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition
title_fullStr Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition
title_full_unstemmed Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition
title_short Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition
title_sort intensity modulated radiotherapy for high risk prostate cancer based on sentinel node spect imaging for target volume definition
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1190164/
https://www.ncbi.nlm.nih.gov/pubmed/16048656
http://dx.doi.org/10.1186/1471-2407-5-91
work_keys_str_mv AT ganswindtute intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT paulsenfrank intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT corvinstefan intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT eichhornkai intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT glockerstefan intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT hundtilse intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT birknermattias intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT albermarkus intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT anastasiadisaristotelis intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT stenzlarnulf intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT baresroland intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT budachwilfried intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT bambergmichael intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition
AT belkaclaus intensitymodulatedradiotherapyforhighriskprostatecancerbasedonsentinelnodespectimagingfortargetvolumedefinition